|
|
白蛋白结合型紫杉醇在胃癌治疗中的最新临床研究进展
|
Abstract:
胃癌是最常见的恶性肿瘤之一，我国是胃癌的高发区域，化疗是治疗胃癌的主要方法之一。在胃癌化疗药物中主要的药物包含紫杉醇类、铂类、氟化嘧啶类等。白蛋白结合型紫杉醇(NAB-P)为紫杉醇的特殊靶向制剂，近年来在胃癌治疗方面的临床应用逐渐增多，大量研究表明其疗效性及安全性较好。本文就白蛋白结合型紫杉醇在胃癌治疗中最新研究进展作一综述。
Gastric cancer is one of the most common malignant tumors. My country is a high-incidence area for gastric cancer. Chemotherapy is one of the main methods to treat gastric cancer. The main drugs used in gastric cancer chemotherapy drugs include paclitaxel, platinum, and fluorinated pyrimidines. Albumin-bound paclitaxel (NAB-P) is a special targeted preparation of paclitaxel. In recent years, its clinical application in the treatment of gastric cancer has gradually increased. A large number of studies have shown that its efficacy and safety are better. This article reviews the latest research progress of albumin-bound paclitaxel in the treatment of gastric cancer.
| [1] | 解李丽, 杨同江, 张翠平, 单衍强. 白蛋白结合型紫杉醇的临床研究进展[J]. 药学研究, 2014, 33(5): 289-291.
https://doi.org/10.13506/j.cnki.jpr.2014.05.014 |
| [2] | 秦洁莉. 白蛋白结合型紫杉醇的作用机制和其给药系统的研究进展[J]. 北方药学, 2014, 11(9): 71-74. |
| [3] | Hwang, B.D., Lee, Y.C., Huh, D.S., et al. (2001) Promotion of Microtubule Assembly in Vitro by Novel 28-KDA Protein Purified from Human Placenta. European Journal of Cancer, 37, S279.
https://doi.org/10.1016/S0959-8049(01)81523-9 |
| [4] | Schiff, P.B. and Horwitz, S.B. (1980) Taxol Stabilizes Microtubules in Mouse Fibroblast Cells. Proceedings of the National Academy of Sciences of the United States of America, 77, 1561-1565. https://doi.org/10.1073/pnas.77.3.1561 |
| [5] | 徐佳茗, 夏学军, 刘玉玲. 紫杉醇新型制剂及临床研究进展[J]. 实用药物与临床, 2016, 19(4): 510-517. |
| [6] | 刘子田, 王晓阳, 祝新, 毛佳佳, 刘志, 武群政, 孙富云, 姚伦锦, 金明新. 白蛋白结合型紫杉醇联合奥沙利铂和替吉奥在局部不可切除的进展期胃癌转化治疗中的应用[J]. 中国现代普通外科进展, 2021, 24(5): 374-377+383. |
| [7] | Cheng, X., Wu, D., Xu, N., Chen, L., Yan, Z., Chen, P., Zhou, L., Yu, J., Cui, J., Li, W., Wang, C., Feng, W., Wei, Y., Yu, P., Du, Y., Ying, J., Xu, Z., Yang, L. and Zhang, Y. (2021) Adjuvant Albumin-Bound Paclitaxel Combined with S-1 vs. Oxaliplatin Combined with Capecitabine after D2 Gastrectomy in Patients with Stage III Gastric Adenocarcinoma: A Phase III Multicenter, Open-Label, Randomized Controlled Clinical Trial Protocol. BMC Cancer, 21, Article No. 56. https://doi.org/10.1186/s12885-020-07772-7 |
| [8] | Xiong, J., Han, S., Ding, S., He, J. and Zhang, H. (2018) Antibody-Nanoparticle Conjugate Constructed with Trastuzumab and Nanoparticle Albumin-Bound Paclitaxel for Targeted Therapy of Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer. Oncology Reports, 39, 1396-1404. https://doi.org/10.3892/or.2018.6201 |
| [9] | 刘辉, 施俊. 晚期胃癌治疗的研究进展[J]. 现代肿瘤医学, 2021, 29(23): 4226-4229. |
| [10] | 陈磊, 王玉琴, 曹齐生, 何昌霞. 白蛋白紫杉醇治疗老年晚期胃癌患者临床疗效及安全性[J]. 中国老年学杂志, 2021, 41(21): 4660-4662. |
| [11] | 白春华. 白蛋白结合型紫杉醇联合化疗三线治疗晚期胃癌的疗效[J]. 世界复合医学, 2021, 7(5): 183-186. |
| [12] | Shitara, K., Takashima, A., Fujitani, K., Koeda, K., Hara, H., Nakayama, N., Hironaka, S., Nishikawa, K., Makari, Y., Amagai, K., Ueda, S., Yoshida, K., Shimodaira, H., Nishina, T., Tsuda, M., Kurokawa, Y., Tamura, T., Sasaki, Y., Morita, S. and Koizumi, W. (2017) Nab-Paclitaxel versus Solvent-Based Paclitaxel in Patients with Previously Treated Advanced Gastric Cancer (ABSOLUTE): An Open-Label, Randomised, Non-Inferiority, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 2, 277-287. https://doi.org/10.1016/S2468-1253(16)30219-9 |
| [13] | Hirata, K., Hamamoto, Y., Ando, M., Imamura, C.K., Yoshimura, K., Yamazaki, K., Hironaka, S. and Muro, K. (2020) Weekly Paclitaxel Plus Ramucirumab versus Weekly Nab-Paclitaxel Plus Ramucirumab for Unresectable Advanced or Recurrent Gastric Cancer with Peritoneal Dissemination Refractory to First-Line Therapy—The P-SELECT Trial (WJOG10617G)—A Randomised Phase II Trial by the West Japan Oncology Group. BMC Cancer, 20, Article No. 548. https://doi.org/10.1186/s12885-020-07047-1 |
